Clinical research during the COVID-19 pandemic: The role of virtual visits and digital approaches.
COVID-19 pandemic
clinical trials
virtual systems
Journal
Journal of clinical and translational science
ISSN: 2059-8661
Titre abrégé: J Clin Transl Sci
Pays: England
ID NLM: 101689953
Informations de publication
Date de publication:
08 Mar 2021
08 Mar 2021
Historique:
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
Clinical trials are a fundamental tool in evaluating the safety and efficacy of new drugs, medical devices, and health system interventions. Clinical trial visits generally involve eligibility assessment, enrollment, intervention administration, data collection, and follow-up, with many of these steps performed during face-to-face visits between participants and the investigative team. Social distancing, which emerged as one of the mainstay strategies for reducing the spread of SARS-CoV-2, has presented a challenge to the traditional model of clinical trial conduct, causing many research teams to halt all in-person contacts except for life-saving research. Nonetheless, clinical research has continued during the pandemic because study teams adapted quickly, turning to virtual visits and other similar methods to complete critical research activities. The purpose of this special communication is to document this rapid transition to virtual methodologies at Clinical and Translational Science Awards hubs and highlight important considerations for future development. Looking beyond the pandemic, we envision that a hybrid approach, which implements remote activities when feasible but also maintains in-person activities as necessary, will be adopted more widely for clinical trials. There will always be a need for in-person aspects of clinical research, but future study designs will need to incorporate remote capabilities.
Identifiants
pubmed: 34192057
doi: 10.1017/cts.2021.19
pii: S2059866121000194
pmc: PMC8185429
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e102Subventions
Organisme : NCATS NIH HHS
ID : U01 TR002626
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR002260
Pays : United States
Organisme : NIDA NIH HHS
ID : UG1 DA013727
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001450
Pays : United States
Informations de copyright
© The Association for Clinical and Translational Science 2021.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Pilot Feasibility Stud. 2017 Jul 6;4:14
pubmed: 28694993
NPJ Digit Med. 2019 Dec 12;2:126
pubmed: 31872066
Ther Innov Regul Sci. 2020 Sep;54(5):1141-1151
pubmed: 32128701
Contemp Clin Trials Commun. 2018 Aug 07;11:156-164
pubmed: 30112460
Semin Perinatol. 2020 Nov;44(7):151287
pubmed: 32807490
J Am Coll Cardiol. 2020 Nov 17;76(20):2368-2378
pubmed: 33183511
Healthc Inform Res. 2017 Jan;23(1):4-15
pubmed: 28261526
NPJ Digit Med. 2020 Jul 31;3:101
pubmed: 32821856
Leukemia. 2020 Aug;34(8):2000-2011
pubmed: 32444866
Nicotine Tob Res. 2020 Dec 12;22(12):2134-2140
pubmed: 32531046
Mayo Clin Proc Innov Qual Outcomes. 2020 Jun 05;4(3):305-314
pubmed: 32542222